Alnylam Pharmaceuticals Shares Drop 1.29% With 0.37 Billion Volume Ranking 263rd as Clinical Advances Continue

On August 29, 2025, Alnylam Pharmaceuticals (ALNY) closed at a 1.29% decline, with a trading volume of 0.37 billion, ranking 263rd in market activity. The stock’s recent performance may reflect ongoing developments in its clinical pipeline.

The company announced updated results from its Phase 2 CAA study, evaluating ALN-APP for cerebral amyloid angiopathy. The trial, which began in April 2024, is expected to complete its primary phase by 2025. Positive interim data could bolster investor confidence, particularly in the neurological treatment sector.

Additionally, Alnylam’s Zilebesiran, an RNAi therapeutic for hypertension, met its primary endpoint in the KARDIA-1 Phase 2 trial. This outcome supports its potential for long-term cardiovascular risk management and may influence upcoming regulatory discussions.

The stock’s mixed performance underscores the balance between clinical progress and market skepticism. Analysts remain divided, with a moderate buy consensus based on recent coverage. Institutional ownership remains high, indicating sustained institutional interest.